Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This 52-week multicenter open-labeled extension study is designed to assess the long-term
safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is
open to patients who have completed core study CLAF237A1303.